¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-17
±³À°ÀÏÀÚ : 2021-04-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 20000¿ø/ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ: 10000¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ09:00~09:20 What Is Clonal Hematopoiesis of Indeterminate Potential (CHIP)?  S. Jaiswal(Stanford Univ. USA) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ09:20~09:40 CHIP, A Common Risk Factor for Cardiology and Oncology  °í¿µÀÏ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ09:40~10:00 CHIP and Atherosclerotic Cardiovascular Disease  ÀÌÈñ¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ10:00~10:20 How Will We Use CHIP in Clinical Practice?  À̼±±â(ÇѸ²ÀÇ´ë) 
Åä·Ð 04¿ù 17ÀÏ ¿Â¶óÀΠ10:20~10:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ04¿ù 17ÀÏ  10:30~10:40 Break  () 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ10:40~11:00 Role of Myocardial Viability Imaging in Post-STICH Era: Interventionist Perspectives  ¾ÈÁ¤¹Î(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ11:00~11:20 Viability Imaging: ECHO and Cardiologist Perspectives  Á¶Àͼº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ11:20~11:40 Myocardial Viability: MRI  ¹Úöȯ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ11:40~12:00 Myocardial Viability: PET/SPECT  Á¶»ó°Ç(Àü³²ÀÇ´ë) 
Åä·Ð 04¿ù 17ÀÏ ¿Â¶óÀΠ12:00~12:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ04¿ù 17ÀÏ  12:10~12:15 Break  () 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ12:15~12:35 Combination Therapy of Antihypertensive Drugs for Cardiovascular Protection  ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ12:35~12:55 Why Should We Consider Strongly Rosuvastatin Ezetimibe Combination Therapy?  ÇÑÁ¤±Ô(¼­¿ïÀÇ´ë) 
È޽Ġ04¿ù 17ÀÏ  12:55~13:10 Break  () 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ13:10~13:30 Diverse causes of pulmonary vein stenosis  ±èÁö³ª(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ13:30~13:50 Diagnosis and medical management of pulmonary vein stenosis  Á¤¼öÀÎ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ13:50~14:10 Transcatheter treatment of pulmonary vein stenosis  ±è±â¹ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ14:10~14:30 Best surgical strategy to prevent re-stenosis of pulmonary vein stenosis  ¹Úõ¼ö(¿ï»êÀÇ´ë) 
Åä·Ð 04¿ù 17ÀÏ ¿Â¶óÀΠ14:30~14:40 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ04¿ù 17ÀÏ  14:40~14:50 Break  () 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ14:50~15:10 TAVR Valve Leaflet Thrombosis and a Role of CFD Analysis  ÀÌ°ü¿ë(°¡Å縮ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ15:10~15:30 Hemodynamic Characteristics Around a Vulnerable Stenosis  ÃÖ¿ì¶ô(POSTECH) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ15:30~15:50 Deep Learning Models for Predicting Lung Diseases Such as COPD and COVID-19  ÃÖ»óÇå(°æºÏ´ëÇб³) 
±³À°½Ã°£ 04¿ù 17ÀÏ ¿Â¶óÀΠ15:50~16:10 Convolutional Neural Network Method for Classification of Heart Sounds  À¯µ¿Çö(POSTECH) 
Åä·Ð 04¿ù 17ÀÏ ¿Â¶óÀΠ16:10~16:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÀåÇÐȸ (¿Â¶óÀÎ) 2021³â Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2021-04-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021³â Çѱ¹È£½ºÇǽº¡¤¿ÏÈ­ÀÇ·áÇÐȸ Ãá°è¿¬¼ö°­Á : 2021-04-17
´ÙÀ½±Û ¼­¿ïƯº°½ÃÀÇ»çȸ (¿Â¶óÀÎ) 2021³â ¼ÛÆı¸ÀÇ»çȸ ¿Â¶óÀÎ ¿¬¼ö±³À°(4¿ù) : 2021-04-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20820 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ – Á¦31ȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­Á : 2024-06-16 0 14 2024-05-27
20819 ºÎ»ê ´ëÇÑÀ̽ÄÇÐȸ 2024³â ½ÅÀåÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-16 0 9 2024-05-27
20818 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-16 0 18 2024-05-27
20817 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ¾ð¾î°Ë»ç ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-06-16 0 16 2024-05-27
20816 ¼­¿ï Á¦28ȸ ¼­¿ï½Ã³»°úÀÇ»çȸ Á¤±âÃÑȸ ¹× Çмú´ëȸ : 2024-06-16 0 34 2024-05-27
20815 ¼­¿ï 2024³â Á¦16ȸ °æÈñ´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-16 0 26 2024-05-27
20814 ºÎ»ê 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿µ³²¼Ò¾Æ¾Ë·¹¸£±â ½ÉÆ÷Áö¿ò : 2024-06-16 0 17 2024-05-27
20813 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦23Â÷ ½Å»ý¾Æ¼Ò»ý¼ú workshop : 2024-06-16 0 26 2024-05-27
20812 ¼­¿ï 2024³â ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ ÀÇÇÐÀ¯ÀüÇÐ Primer Course : 2024-06-16 0 42 2024-05-27
20811 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 43 2024-05-27
20810 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú ÄÄÇ»Åͼö¼úÇÐȸ - Á¦3ȸ ±¹Á¦ ·Îº¿¼ö¼ú ½ÉÆ÷Áö¾ö : 2024-06-15 0 7 2024-05-27
20809 °æ±â ´ëÇѺñ¸¸ÇÐȸ Á¦18ȸ ODOT (One Day Course of Obesity Treatment) : 2024-06-15 0 13 2024-05-27
20808 ¼­¿ï 2024³â Á¦ 1ȸ ºñ¸¸ ¿¬¼ö°­ÁÂ(ObesityCare Pro) : 2024-06-15 0 6 2024-05-27
20807 ¼­¿ï 2024 °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 7 2024-05-27
20806 ¼­¿ï ´ëÇѼöºÎ¿Ü°úÇÐȸ ¼öºÎ»óÁö ÇÏ°èÇмú´ëȸ : 2024-06-15 0 8 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷